Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
101
-
Total 13F shares, excl. options
-
56.3M
-
Shares change
-
-784K
-
Total reported value, excl. options
-
$57.4M
-
Value change
-
-$2.48M
-
Put/Call ratio
-
0.44
-
Number of buys
-
51
-
Number of sells
-
-52
-
Price
-
$1.02
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q2 2024
141 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q2 2024.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 101 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 56.3M shares
of 236M outstanding shares and own 23.82% of the company stock.
Largest 10 shareholders include BlackRock Inc. (11.6M shares), VANGUARD GROUP INC (9.28M shares), Alerce Investment Management, L.P. (5.75M shares), GEODE CAPITAL MANAGEMENT, LLC (4.54M shares), ACADIAN ASSET MANAGEMENT LLC (4.06M shares), RENAISSANCE TECHNOLOGIES LLC (3.91M shares), STATE STREET CORP (2.75M shares), JACOBS LEVY EQUITY MANAGEMENT, INC (2.09M shares), Qube Research & Technologies Ltd (1.74M shares), and Connor, Clark & Lunn Investment Management Ltd. (1.05M shares).
This table shows the top 101 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.